The US Food and Drug Administration (FDA) has cleared Archeus Technologies’ Investigational New Drug (IND) application for ART-101, a novel receptor-based targeting small molecule for the imaging and treatment of prostate cancer.   This clearance enables the company to initiate a Phase I clinical trial in men with metastatic castration-resistant prostate cancer (mCRPC), which is expected […]